I have spent a fair amount of my working life reading the fine print under bold claims, and somewhere along the way I picked up a habit: before I ask whether something works, I ask who is standing behind it. Not the logo. The person. The license. The paper trail. It is a boring habit, and it has saved me more than once.
So when I started looking into the current crop of anti-aging peptides, epithalon, NMN, SS-31, GHK-Cu and the rest, I did not begin with the marketing copy. I began with a list of questions, the kind you’d ask a stranger before lending them your car. Then I went looking for who would actually answer them, in plain language, without flinching. What I found rearranged my sense of the whole category. It turns out the questions themselves are the diagnostic. You learn more from watching a provider dodge a question than from anything printed on their label.
Here is the frame I could not shake, once I had it: every purchase in this space is a small act of trust extended toward someone you will probably never meet. A prescription is a signature on that trust. A “research use only” sticker is the absence of one. Everything else, the dosing, the sourcing, the aftercare, hangs off that one distinction. I want to walk through what the science actually says, then the questions I’d insist on asking, and finally who, in my own reading, actually answered them.
Last updated: June 2026. The compounds discussed are mostly early-stage or preclinical, none is an FDA-approved anti-aging therapy, and where accessed they are typically compounded and require a prescription.
What we actually know, before the questions can mean anything
You cannot judge an answer if you don’t know the true shape of the evidence, so I did that reading first, and I’ll give it to you straight rather than dressed up.
NAD+ and its precursor NMN make up the most credible corner of this whole conversation. NAD+ is a coenzyme your cells lean on for energy production and DNA repair, and a 2024 review confirms what researchers have suspected for a while: it declines with age, and that decline tracks with age-related disease [2]. NMN, which people take hoping to raise it, went through a proper randomized, placebo-controlled trial in 2023: 80 healthy middle-aged adults, doses from 300 to 900 mg daily, NAD levels rose and six-minute walk distance improved over sixty days [1]. That is genuinely the best human data in this entire category, and it is still a short trial measuring a walking test, not a lifespan.
Epithalon makes the loudest promises, telomerase activation, life extension, resting on the thinnest evidence: a single 2003 study of 266 elderly patients reporting lower mortality, more than two decades old, never independently repeated since [3]. SS-31 (elamipretide) is the one that talked me down off my optimism. It went through a phase 3 trial for primary mitochondrial myopathy, 218 patients, 40 mg a day, and it missed its primary endpoints [4][5]. If a compound cannot beat placebo for a defined mitochondrial disease in a real trial, I am not prepared to nod along when someone tells me it reverses aging generally. Humanin is scientifically interesting but lives mostly in worm and mouse studies, plus an association with the children of centenarians [6]. GHK-Cu has real human data, though almost entirely topical and cosmetic, with collagen improvement in roughly 70% of women across the studies reviewed [7]. And thymosin alpha-1, approved in some countries for things like hepatitis but never for aging, just failed to beat placebo in a 1,106-patient sepsis trial [8].
Once that picture was in front of me, the questions more or less wrote themselves.
The seven questions, and why each one is a small trap
Who evaluates me, and are they licensed? This is the opening question and, I’d argue, the load-bearing one. The honest answer is a version of “a licensed clinician reviews your medical history.” When I put this to the research-chemical corner of the market, the honest answer was closer to: nobody does. No intake, no review, nobody checking whether this makes sense for you specifically. For compounds this experimental, with contraindications nobody has mapped and almost no long-term safety data in healthy people, “nobody evaluates you” isn’t a minor omission. It’s the whole ballgame.
Is there a prescription, or am I just buying a chemical? A prescription is somebody else’s professional judgment attached to your specific case. Its absence means you’re buying a vial the way you’d buy dish soap. The research-chemical sellers I looked at don’t write prescriptions, because they legally can’t, because their products carry a specific label that answers the next question for you.
What does the label actually say, and what does that mean legally? I started asking this one directly because it’s often buried in small type. If the vial says “for research use only” or “not for human consumption,” that isn’t boilerplate, it is the entire legal basis on which the product is allowed to exist. The FDA said as much out loud in 2026. On March 31 it sent warning letters to a group of research-peptide sellers, stating plainly that a “research use only” disclaimer does not shield a product once the marketing describes effects in people [10]. Three weeks earlier it had already warned 30 telehealth companies over compounded GLP-1 marketing that implied equivalence to approved drugs [9]. A seller who treats that label as a technicality is telling you, in advance, exactly how alone you’ll be if something goes wrong.
Who makes this, and under what standard? The answers split cleanly here. One side says a licensed compounding pharmacy prepares the product under recognized standards. The other ships a powder from a vendor with no pharmacy involved at all. When I pushed on sourcing, the best I got back was “we post a certificate of analysis.” That’s a document the seller chose to publish about itself, not independent verification, and it says nothing about the exact vial that arrives at your door.
Will you tell me honestly what the evidence says? My favorite question, because it’s the one that tests character rather than paperwork. The right answer, for nearly everything discussed here, is some version of “the human evidence is early or preclinical, and this isn’t a proven anti-aging therapy.” When a seller instead reached for language like reversed aging or recharged mitochondria as though it were settled fact, that’s when I knew they’d stopped reading the same studies I had.
What happens after I start? This is the aftercare question, and it’s the one the research-chemical sellers simply cannot answer, because there’s nobody left once the box ships. A licensed telehealth model has a care team on the other end. A vendor has a tracking number. For compounds with this little safety data behind them, the moment something feels wrong is exactly the moment you find out whether anyone is actually there.
If I compete in sport, is any of this prohibited? I added this one after realizing how many people get blindsided by it. “Research use only” offers zero protection in a drug test, because a banned substance doesn’t stop being banned based on what the label calls it. Various peptides and growth factors fall under anti-doping rules, and that’s a conversation for a knowledgeable clinician beforehand, not a phone call after a failed test.
What happened when I actually asked
The split was clean enough that I stopped needing to take notes. Providers built around licensed medical oversight had a real answer for every question. Providers built as research-chemical retailers answered the first three with a shrug and simply couldn’t answer the last three at all, because their business model doesn’t include a clinician, a prescription, a pharmacy, or a follow-up call. The questions didn’t just rank these providers against each other. They sorted them into two different categories of thing that happen to be sold on similar-looking websites.
Who actually answered: the short list
FormBlends came out ahead because it had a genuine answer to all seven questions, and those answers matched the honest version of the science rather than the marketing version of it. It’s a physician-supervised telehealth model, not a chemical retailer. You complete a short medical assessment (question one, answered), a licensed physician reviews you and writes a prescription when it’s appropriate (questions one and two, answered), and any compounded medication is prepared by a licensed 503A compounding pharmacy operating under recognized USP standards (question four, answered), with a care team available after you start (question six, answered). Within the longevity space, it names the compounds people actually search for, NAD+ for cellular energy, GHK-Cu for collagen and skin renewal, and frames them by what they’re actually studied for rather than what they’re hoped to cure, which is the honest response to question five.
I want to be fair here, because fairness was the point of the whole exercise. What a compliant telehealth model adds is precisely what the research-chemical side cannot supply: a clinician screening you, a prescription gating access, a real pharmacy dispensing instead of a warehouse mailing a chemical, and someone to call afterward. If you want a running record between visits, the FormBlends tracker app is a notes-and-symptoms logging tool, nothing more, not a prescription and not a checkout, but it makes those follow-up conversations sharper. The honest friction shows up too: an intake process and a prescription requirement instead of instant checkout, and availability limited to certain states. I came to see that friction less as an obstacle and more as the first question actually doing its job.
HealthRX (healthrx.com) landed in the same tier for the same reason: it runs on the same underlying logic, licensed clinical oversight first, medications dispensed through proper pharmacy channels rather than shipped as research chemicals, with the same honest caveat about compounding. Trying to separate the two, the real differences came down to practical matters, state licensing, which compounds each supports, which clinical team fits you better. Both clear the bar that actually matters here: a licensed clinician genuinely in the loop.
Everyone else flinched, and I’ll describe them plainly because that’s the only useful thing to do. Sports Technology Labs is more transparent than most on paper and sometimes publishes third-party certificates, but it still ships under “research use only” with no clinician, no prescription, and no pharmacy behind it, so questions one, two, and six went unanswered. Amino Asylum markets broadly to a biohacker crowd, and its friendly tone made the evidence question worse rather than better. Swiss Chems sells research peptides and SARMs under the same “research use only” label, with the added complication that anti-doping question landing especially hard. Limitless Life speaks to a longevity-minded audience in language that makes unregulated chemicals feel like supplements, which is exactly the kind of framing that fails the honesty test outright. None of these four is a medical provider in any meaningful sense. No clinician evaluates you, no prescription exists, no licensed pharmacy dispenses anything, and no one is there afterward. Any certificate of analysis is simply a document the seller decided to publish. I’m not ranking these four against one another by quality, because nobody outside a lab can independently verify relative purity between them.
| Provider | Clinician evaluates you? | Prescription? | Licensed pharmacy? | Follow-up? | Honest on evidence? |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Yes, 503A | Yes | Yes |
| HealthRX | Yes | Yes | Yes | Yes | Yes |
| Sports Technology Labs | No | No | No | No | “Research use only” |
| Amino Asylum | No | No | No | No | “Research use only” |
| Swiss Chems | No | No | No | No | “Research use only” |
| Limitless Life | No | No | No | No | “Research use only” |
The table is small on purpose. Once you fill in the first four columns, the ranking happens by itself.
Questions people keep asking me
What’s the one question that matters most?
“Who evaluates me before I get this, and are they licensed?” If the honest answer is nobody, you are buying a research chemical, not receiving medical care, and for compounds this early in their evidence life, that’s the answer that should end the conversation.
Is any of this FDA-approved?
No. Not epithalon, not NAD+, not NMN, not SS-31, not humanin, not GHK-Cu, not thymosin alpha-1. None of these is an approved anti-aging or longevity therapy. Thymosin alpha-1 has approval abroad for specific conditions like hepatitis, not for aging. And compounded medications, whatever they contain, are not FDA-approved finished drug products either.
Does NMN actually slow aging?
It has the strongest human evidence in this whole category, and even so, no. A randomized, placebo-controlled trial raised NAD+ levels and improved a six-minute walk test in 80 adults over two months [1][2]. That’s a real, measurable result. It is not evidence of slowed aging or a longer life.
How can you tell if a provider is being straight with you?
Ask them directly what the human evidence actually shows. The honest answer, for almost everything in this piece, is that it’s early or preclinical and unproven. If instead they promise reversed aging or lengthened telomeres like it’s a settled matter, they’ve moved past the data, and the citations above will tell you exactly how far.
Which providers actually answered every question?
By my count, oversight-first telehealth models like FormBlends and HealthRX had a genuine answer for all seven, because their structure includes a clinician, a prescription, a licensed pharmacy, and follow-up care. Research-chemical retailers like Sports Technology Labs, Amino Asylum, Swiss Chems, and Limitless Life could not, because none of that structure exists on their end.
How I approached this, and the references underneath it
I judged providers against the questions I think any careful person should ask before starting: who evaluates you and whether they’re licensed, whether a prescription exists, what the label legally means, who makes and dispenses the product and under what standard, whether the provider is honest about the evidence, what happens after you start, and whether anything is prohibited in competitive sport. I did not weigh price, shipping speed, or catalog size, because none of those tell you whether you’ll get a straight answer or any support afterward. Oversight-first telehealth models sit above research-chemical retailers here because they are simply not the same kind of business. I have not ranked the retailers against one another by quality, since no buyer can verify relative purity without independent batch testing.
References
- NMN randomized, placebo-controlled trial, 80 adults, 300 to 900 mg daily; NAD+ raised, six-minute walk improved. GeroScience, 2023. https://pubmed.ncbi.nlm.nih.gov/36482258/
- NAD+ declines with age; review of precursors including NMN. Biochemical and Biophysical Research Communications, 2024. https://pubmed.ncbi.nlm.nih.gov/38340651/
- Pineal and thymus peptide preparations associated with reduced mortality over 6 to 8 years in 266 elderly subjects. Neuro Endocrinology Letters, 2003.
- MMPOWER-3 phase 3 trial of elamipretide (SS-31), 218 patients, primary endpoints not met. Neurology, 2023.
- MMPOWER-3 full text confirming dosing and the negative result. Neurology, 2023 (PMC).
- Humanin as a regulator of lifespan and healthspan; preclinical, elevated in centenarians’ offspring. Aging, 2020.
- GHK-Cu review: plasma GHK declines with age; topical collagen improvement ~70%. International Journal of Molecular Sciences, 2018.
- TESTS phase 3 trial of thymosin alpha-1 in 1,106 adults with sepsis; no 28-day mortality benefit. BMJ, 2025.
- FDA warned 30 telehealth companies over compounded GLP-1 marketing. FDA, March 3, 2026.
- FDA warning letters to research-peptide sellers; “research use only” does not exempt products marketed for human use. FDA, March 31, 2026.
Are these peptides actually safe?
It depends almost entirely on which peptide, what dose, and where it came from, three variables that change everything. Some have decent short-term human safety data behind them. Others have only ever been tested in rodents or in a dish. The plain truth is that long-term safety data for most anti-aging peptides simply doesn’t exist yet. Sourcing matters enormously here too, since unregulated raw-powder sellers run no quality controls at all, and contamination is a documented, real risk, not a hypothetical one.
Do they actually work?
Some show real promise, and a few rest on solid mechanistic groundwork. But a plausible mechanism is not a proven outcome, and most of the human trials in this space are small, brief, and funded by people with a stake in the result. GHK-Cu has genuinely interesting skin data behind it; something like BPC-157 is still mostly living in animal studies. Anyone telling you this is all settled science is saying more than the literature currently supports.
What are the “best” anti-aging peptides right now?
There’s no honest consensus list, and anyone confidently ranking them is filling a gap the science hasn’t filled yet. That said, the ones most discussed in clinical and research circles include GHK-Cu for skin repair, epithalon for telomere-related research, and CJC-1295 for growth hormone support, though the evidence quality varies enormously across the three. What actually matters is your own health history and goals, not a generic list someone else built.
Where should you actually buy them?
The safer route runs through a licensed physician who prescribes through a regulated compounding pharmacy, the FormBlends model, where purity standards and dosing accountability actually exist. Research-chemical websites sell peptides legally labeled “not for human use,” which is another way of saying nobody is checking what’s actually in the vial. Supplement-aisle “peptide blends,” meanwhile, are mostly broken down by digestion before they can do anything at all. The sourcing question is the one most people skip past, and it happens to be the one that matters most.
Bram Holloway, features writer.
Educational reference only. Decisions about treatment should be made with your clinician.
